Mainz Biomed (MYNZ) Competitors

Mainz Biomed logo
$6.07 -0.46 (-7.03%)
As of 03:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MYNZ vs. BLUE, IMRX, HOWL, OPTN, VTVT, KRON, UNCY, ACHL, ALXO, and IMMX

Should you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include bluebird bio (BLUE), Immuneering (IMRX), Werewolf Therapeutics (HOWL), OptiNose (OPTN), vTv Therapeutics (VTVT), Kronos Bio (KRON), Unicycive Therapeutics (UNCY), Achilles Therapeutics (ACHL), ALX Oncology (ALXO), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.

Mainz Biomed vs.

Mainz Biomed (NASDAQ:MYNZ) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.

Mainz Biomed has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Mainz Biomed's return on equity of 0.00% beat bluebird bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Mainz BiomedN/A N/A N/A
bluebird bio -565.74%-322.46%-53.17%

bluebird bio received 1026 more outperform votes than Mainz Biomed when rated by MarketBeat users. However, 73.68% of users gave Mainz Biomed an outperform vote while only 70.99% of users gave bluebird bio an outperform vote.

CompanyUnderperformOutperform
Mainz BiomedOutperform Votes
14
73.68%
Underperform Votes
5
26.32%
bluebird bioOutperform Votes
1040
70.99%
Underperform Votes
425
29.01%

Mainz Biomed has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Mainz Biomed currently has a consensus target price of $67.00, suggesting a potential upside of 926.03%. bluebird bio has a consensus target price of $49.14, suggesting a potential upside of 577.83%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts plainly believe Mainz Biomed is more favorable than bluebird bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mainz Biomed
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
bluebird bio
2 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Mainz Biomed has higher earnings, but lower revenue than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mainz Biomed$900K14.51-$26.30M-$65.60-0.10
bluebird bio$29.50M2.39-$211.91M-$37.40-0.19

In the previous week, Mainz Biomed had 2 more articles in the media than bluebird bio. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for bluebird bio. bluebird bio's average media sentiment score of 0.00 beat Mainz Biomed's score of -0.39 indicating that bluebird bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mainz Biomed
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
bluebird bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

87.4% of bluebird bio shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 1.4% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Mainz Biomed beats bluebird bio on 10 of the 17 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYNZ vs. The Competition

MetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$14.51M$7.03B$5.86B$9.16B
Dividend YieldN/A2.90%5.26%4.00%
P/E Ratio-0.104.3316.6114.66
Price / Sales14.51322.96468.2678.04
Price / CashN/A75.4646.0938.87
Price / Book0.605.577.465.07
Net Income-$26.30M$123.72M$3.19B$222.90M
7 Day Performance-11.88%-0.10%0.86%1.23%
1 Month Performance23.44%2.72%4.78%4.23%
1 Year Performance-84.00%3.56%24.08%20.29%

Mainz Biomed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYNZ
Mainz Biomed
3.0225 of 5 stars
$6.07
-7.0%
$67.00
+1,003.6%
-83.7%$12.20M$900,000.00-0.0930Analyst Forecast
BLUE
bluebird bio
1.7383 of 5 stars
$6.10
-3.0%
$49.14
+705.8%
-63.1%$59.34M$29.50M-0.16520News Coverage
IMRX
Immuneering
3.4829 of 5 stars
$1.87
-1.8%
$12.20
+554.2%
-69.0%$57.91M$320,000.00-0.9560Short Interest ↓
HOWL
Werewolf Therapeutics
2.3495 of 5 stars
$1.29
-5.4%
$9.33
+625.8%
-74.3%$57.71M$19.94M-0.8540Positive News
OPTN
OptiNose
4.0459 of 5 stars
$5.74
-1.3%
$16.67
+190.6%
-70.5%$57.69M$75.67M-1.37190Short Interest ↑
VTVT
vTv Therapeutics
1.4758 of 5 stars
$17.98
+0.6%
$35.00
+94.7%
+100.0%$57.34M$2.02M-3.979Gap Down
KRON
Kronos Bio
3.5653 of 5 stars
$0.95
-2.1%
$1.63
+71.1%
-1.9%$57.32M$6.29M-0.66100News Coverage
UNCY
Unicycive Therapeutics
3.9343 of 5 stars
$0.55
-3.3%
$5.50
+905.5%
-46.7%$56.57M$680,000.00-0.569Short Interest ↓
Positive News
High Trading Volume
ACHL
Achilles Therapeutics
3.6543 of 5 stars
$1.38
-0.4%
$4.00
+190.9%
+46.3%$56.51MN/A-0.83250Short Interest ↓
News Coverage
ALXO
ALX Oncology
3.899 of 5 stars
$1.06
-3.2%
$3.05
+189.1%
-92.4%$55.64MN/A-0.3540Positive News
IMMX
Immix Biopharma
3.4105 of 5 stars
$2.01
flat
$7.00
+248.3%
-29.2%$55.30MN/A-2.369Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:MYNZ) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners